The immuno-oncological challenge of COVID-19.

Abstract

Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.

• Authors: Lisa Derosa, Cléa Melenotte, Franck Griscelli, Bertrand Gachot, Aurélien Marabelle, Guido Kroemer, Laurence Zitvogel
• Journal: Nature cancer (Nat Cancer) Vol. 1 Issue 10 Pg. 946-964 (10 2020) ISSN: 2662-1347 [Electronic] England
• PMID: 35121872 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2020. Springer Nature America, Inc.

Topics

• COVID-19 (immunology)
• Humans
• SARS-CoV-2